|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Migliore L, Migheli F, Spisni R and
Coppedè F: Genetics, cytogenetics, and epigenetics of colorectal
cancer. J Biomed Biotechnol. 2011:7923622011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Segal NH and Saltz LB: Evolving treatment
of advanced colon cancer. Annu Rev Med. 60:207–219. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bardhan K and Liu K: Epigenetics and
colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kulis M and Esteller M: DNA methylation
and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baylin SB: DNA methylation and gene
silencing in cancer. Nat Clin Pract Oncol. 2(Suppl 1): S4–S11.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakajima T, Enomoto S and Uschijima T: DNA
methylation: A marker for carcinogen exposure and cancer risk.
Environ Health Prev Med. 13:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ye T, Chen Y and Fang J: DNA methylation
biomarkers in serum for gastric cancer screening. Mini Rev Med
Chem. 10:1034–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shivapurkar N and Gazdar AF: DNA
methylation based biomarkers in non-invasive cancer screening. Curr
Mol Med. 10:123–132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aarthy R, Mani S, Velusami S, Sundarsingh
S and Rajkumar T: Role of circulating cell-free DNA in cancers. Mol
Diagn Ther. 19:339–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jahr S, Hentze H, English S, Hardt D,
Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood
plasma of cancer patients: Quantitations and evidence for their
origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665.
2001.PubMed/NCBI
|
|
12
|
Gormally E, Caboux E, Vineis P and Hainaut
P: Circulating free DNA in plasma or serum as a biomarker of
carcinogenesis: Practical aspects and biological significance.
Mutat Res. 635:105–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jung K, Fleischhacker M and Rabien A:
Cell-free DNA in the blood as a solid tumor biomarker-a critical
appraisal of the literature. Clin Chim Acta. 411:1611–1624. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bardhan K and Liu K: Epigenetics and
colorectal cancer pathogenesis. Cancer (Basel). 5:676–713. 2013.
View Article : Google Scholar
|
|
15
|
Richter AM, Pfeifer GP and Dammann RH: The
RASSF proteins in cancer; From epigenetic silencing to functional
characterization. Biochim Biophys Acta. 1796:114–128.
2009.PubMed/NCBI
|
|
16
|
Oliveira C, Velho S, Domingo E, Preto A,
Hofstra RM, Hamelin R, Yamamoto H, Seruca R and Schwartz S Jr:
Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations
occur preferentially in MSI sporadic colorectal cancer. Oncogene.
24:7630–7634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dammann R, Li C, Yoon JH, Chin PL, Bates S
and Pfeifer GP: Epigenetic inactivation of a RAS association domain
family protein from lung tumour suppressor locus 3p21.3. Nat Genet.
25:315–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Donninger H, Vos MD and Clark GJ: The
RASSF1A tumor suppressor. J Cell Sci. 120:3163–3172. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoon JH, Dammann R and Pfeifer GP:
Hypermethylation of the CpG island of the RASSF1A gene in
ovarian and renal cell carcinomas. Int J Cancer. 94:212–217. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakamoto N, Terai T, Ajioka Y, Abe S,
Kobayasi O, Hirai S, Hino O, Watanabe H, Sato N, Shimoda T and
Fujii H: Frequent hypermethylation of RASSF1A in early
flat-type colorectal tumors. Oncogene. 23:8900–8907. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyoshi Y, Nagase H, Ando H, Horii A,
Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T and Nakamura Y:
Somatic mutations of the APC gene in colorectal tumors:
Mutation cluster region in the APC gene. Hum Mol Genet.
1:229–233. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rosin-Arbesfeld R, Townsley F and Bienz M:
The APC tumour suppressor has a nuclear export function. Nature.
406:1009–1012. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morin PJ, Sparks AB, Korinek V, Barker N,
Clevers H, Vogelstein B and Kinzler KW: Activation of
beta-catenin-Tcf signaling in colon cancer by mutations in
beta-catenin or APC. Science. 275:1787–1790. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schneikert J and Behrens J: The canonical
Wnt signaling pathway and its APC partner in colon cancer
development. Gut. 56:417–425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Naghibalhossaini F, Zamani M, Mokarram P,
Khalili I, Rasti M and Mostafavi-Pour Z: Epigenetic and genetic
analysis of WNT signaling pathway in sporadic colorectal cancer
patients from Iran. Mol Biol Rep. 39:6171–6178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Esteller M, Sparks A, Toyota M,
Sanchez-Cespedes M, Capella G, Peinado MA, Gonzales S, Tarafa G,
Sidransky D, Meltzer SJ, et al: Analysis of adenomatous polyposis
coli promoter hypermethylation in human cancer. Cancer Res.
60:4366–4371. 2000.PubMed/NCBI
|
|
27
|
Lee S, Hwang KS, Lee HJ, Kim JS and Kang
GH: Aberrant CpG island hypermethylation of multiple genes in
colorectal neoplasia. Lab Invest. 84:884–893. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee BB, Lee EJ, Jung EH, Chun HK, Chang
DK, Song SY, Park J and Kim DK: Aberrant methylation of APC,
MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early
detection of colorectal cancer. Clin Cancer Res. 15:6185–6191.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen SP, Chiu SC, Wu CC, Lin SZ, Kang JC,
Chen YL, Lin PC, Pang CY and Harn HJ: The association of
methylation in the promoter of APC and MGMT and the
prognosis of Taiwanese CRC patients. Genet Test Mol Biomarkers.
13:67–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clément G, Bosman FT, Fontolliet C and
Benhattar J: Monoallelic methylation of the APC promoter is
altered in normal gastric mucosa associated with neoplastic
lesions. Cancer Res. 64:6867–6873. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). Springer.
New York: 2010.
|
|
33
|
Choong MK and Tsafnat G: Genetic and
epigenetic biomarkers of colorectal cancer. Clin Gastroenterol
Hepatol. 10:9–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ghazaleh HA, Chow RS, Choo SL, Pham D,
Olessen JD, Wang RX, Onyskiw C and Baksh S: 14-3-3 mediated
regulation of the tumor suppressor protein, RASSF1A.
Apoptosis. 15:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shivakumar L, Minna J, Sakamaki T, Pestell
R and White MA: The RASSF1A tumor suppressor blocks cell
cycle progression and inhibits cyclin D1 accumulation. Mol Cell
Biol. 22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dallol A, Agathanggelou A, Fenton SL,
Ahmed-Choudhury J, Hesson L, Vos MD, Clark GJ, Downward J, Maher ER
and Latif F: RASSF1A interacts with microtubule-associated
proteins and modulates microtubule dynamics. Cancer Res.
64:4112–4116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wagner KJ, Cooper WN, Grundy RG, Caldwell
G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F and
Maher ER: Frequent RASSF1A tumor suppressor gene promoter
methylation in Wilms' tumor and colorectal cancer. Oncogene.
21:7277–7282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
van Engeland M, Roemen GM, Brink M, Pachen
MM, Weijenberg MP, de Bruïne AP, Arends JW, van den Brandt PA, de
Goeij AF and Herman JG: K-ras mutations and RASSF1A promoter
methylation in colorectal cancer. Oncogene. 21:3792–3795. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gonzalo V, Lozano JJ, Muñoz J, Balaguer F,
Pellisé M, de Rodríguez Miguel C, Andreu M, Jover R, Llor X,
Giráldez MD, et al: Aberrant gene promoter methylation associated
with sporadic multiple colorectal cancer. PLoS One. 5:e87772010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Miladi-Abdennadher I, Abdelmaksoud-Damak
R, Ayadi L, Khabir A, Frikha F, Kallel L, Amouri A, Frikha M,
Sellami-Boudawara T, Gargouri A and Mokdad-Gargouri R:
Hypermethylation of RARβ2 correlates with high COX-2 expression and
poor prognosis in patients with colorectal carcinoma. Tumor Biol.
31:503–511. 2010. View Article : Google Scholar
|
|
41
|
Abouzeid HE, Kassem AM, Wahab Abdel AH,
El-mezayen HA, Sharad H and Abdel Rahman S: Promoter
hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign
and malignant colorectal tumors. Tumor Biol. 32:845–852. 2011.
View Article : Google Scholar
|
|
42
|
Balgkouranidou I, Matthaios D,
Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis
K, Chelis L, Trypsianis G, Chatzaki E, et al: Prognostic role of
APC and RASSF1A promoter methylation status in cell free
circulating DNA of operable gastric cancer patients. Mutat Res.
778:46–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ahlquist T, Bottillo I, Danielsen SA,
Meling GI, Rognum TO, Lind GE, Dallapiccola B and Lothe RA: RAS
signaling in colorectal carcinomas through alteration of RAS, RAF,
NF1, and/or RASSF1A. Neoplasia. 10:680–686. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
An B, Kondo Y, Okamoto Y, Shinjo K,
Kanemitsu Y, Komori K, Hirai T, Sawaki A, Tajika M, Nakamura T, et
al: Characteristic methylation profile in CpG island methylator
phenotype-negative distal colorectal cancers. Int J Cancer.
127:2095–2105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang J, Zheng S, Jin SH and Zhang SZ:
Somatic mutations of APC gene in carcinomas from hereditary
non-polyposis colorectal cancer patients. World J Gastroenterol.
10:834–836. 2010.
|
|
46
|
Kim MS, Lee J and Sidransky D: DNA
methylation markers in colorectal cancer. Cancer Metastasis Rev.
29:181–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kamiyama H, Noda H, Takata O, Suzuki K,
Kawamura Y and Konishi F: Promoter hypermethylation of
tumor-related genes in peritoneal lavage and the prognosis of
patients with colorectal cancer. J Surg Oncol. 100:69–74. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kamiyama H, Noda H, Takata O, Suzuki K,
Kawamura Y and Konishi F: Promoter hypermethylation of
tumor-related genes in peritoneal lavage and the prognosis of
patients with colorectal cancer. J Surg Oncol. 100:69–74. 2009.
View Article : Google Scholar : PubMed/NCBI
|
